These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26104878)

  • 21. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensifying insulin therapy: what options are available to patients with type 2 diabetes?
    Meneghini LF
    Am J Med; 2013 Sep; 126(9 Suppl 1):S28-37. PubMed ID: 23953077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
    Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
    Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes.
    Shanik MH
    Diabetes Technol Ther; 2012 Jun; 14(6):533-9. PubMed ID: 22364142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
    Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
    Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal-Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes.
    Linjawi S; Lee BW; Tabak Ö; Lövdahl S; Werther S; Abusnana S
    Diabetes Ther; 2018 Feb; 9(1):1-11. PubMed ID: 29129018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.
    Tibaldi JM
    Clin Ther; 2011 Nov; 33(11):1630-42. PubMed ID: 22030443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients.
    Pfeiffer KM; Basse A; Lee XY; Waldman LT
    Diabetes Ther; 2018 Oct; 9(5):1931-1944. PubMed ID: 30120755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review.
    Meece J
    Diabetes Ther; 2018 Jun; 9(3):877-890. PubMed ID: 29574634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
    Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
    Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes.
    Martorella AJ
    Postgrad Med; 2011 Jul; 123(4):7-16. PubMed ID: 21680984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
    McCrimmon RJ; Al Sifri S; Emral R; Mohan V; Sauque-Reyna L; Trescolí C; Lalic N; Alvarez A; Demil N; Coudert M; Shaunik A; Bonnemaire M; Rosenstock J;
    Diabetes Obes Metab; 2021 Jun; 23(6):1221-1231. PubMed ID: 33606908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
    Mehta R; Billings LK; Liebl A; Vilsbøll T
    Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?
    Spollett GR
    J Am Acad Nurse Pract; 2012 Apr; 24 Suppl 1():249-59. PubMed ID: 22564101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes.
    Valensi P
    Diabetes Metab Syndr Obes; 2009 Jun; 2():61-71. PubMed ID: 21437119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin initiation and intensification: insights from new studies.
    Kumar A; Kalra S
    J Assoc Physicians India; 2011 Apr; 59 Suppl():17-22. PubMed ID: 21818994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.